Original English content reproduced with permission. Source claims have not been independently validated by Peps MN. Peptide DB ↗
Cartalax (AED peptide)
Bioregulatory Tripeptide | Cartilage & Connective Tissue Support
100-200mcg oral (1-2 capsules) or 700-1400mcg injectable
1-2 times daily with meals (oral) or once daily (injectable)
1-3 months depending on application
Oral capsules: room temperature; Injectable lyophilized: 2-8°C; Reconstituted: 2-8°C refrigerated
Original Peptide DB content reproduced with permission. Source claims have not been independently validated by Peps MN. Source ↗
Synthetic tripeptide developed by Professor Vladimir Khavinson, supporting cartilage, connective tissue, and cellular regeneration through proliferation markers and apoptosis pathway modulation.
Modulates cell proliferation, suppresses apoptosis, affects fibroblast activity, reduces senescence markers, and influences extracellular matrix preservation.
Molecular Data
AE?Alanine
Position 1
Glutamic Acid
Position 2
Asp (AED)
Position 3
Accumulation Curve
Example inputs are illustrative, not a dosing protocol.
Research Indications
Clinical efficacy shown in osteochondrosis, osteoarthritis, and osteoporosis treatment.
Supports cartilage maintenance and joint function.
Supports bone and connective tissue healing.
Increased Ki-67 expression with suppressed apoptosis in young and aged cells.
Enhances collagen synthesis in connective tissue.
Inhibited MMP-9 synthesis; maintained extracellular matrix integrity.
Dosing Protocols
Capsule form; do not chew, swallow whole with water during meals.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Joint Support | 100-200mcg (1-2 capsules) | 1-2x daily with meals | Oral |
Daily subcutaneous injection for enhanced bioavailability.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Tissue Regeneration | 700-1400mcg (10-20mcg/kg) | Daily | SubQ |
Reconstitution Instructions
- Cartalax lyophilized powder
- Bacteriostatic water
- Insulin syringes
- Alcohol swabs
- 1 Use bacteriostatic water for reconstitution
- 2 Gentle mixing required
- 3 Store refrigerated after reconstitution
Solution applied to face, neck, hands, or superficial joint areas.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Skin Rejuvenation | 0.5-1ml solution | 2x daily | Topical |
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
- No reported side effects in Russian clinical use when taken properly
- Well-tolerated in elderly patients
Stop Signs - Discontinue if:
- Allergic reactions
- Digestive upset (rare with proper administration)
- No improvement after 3 months
- Unexpected symptoms
Contraindications
- Pregnancy and breastfeeding
- Active cancer (theoretical proliferation risk)
Quality Checklist
Good Signs
- Professional Russian packaging with holographic seals
- Exactly 0.1mg (100mcg) AC-4 peptide complex per capsule
- Clear Russian/English instructions specifying 'with meals'
Warning Signs
- Proper documentation required for authenticity
- Import verification needed
Bad Signs
- Missing holographic seals or professional packaging
- Unclear dosing instructions
Frequently Asked Questions
How does Cartalax help cartilage if cartilage doesn't have blood vessels to deliver it?
Cartalax works through systemic effects on fibroblasts and gene expression. Once in circulation, it reaches fibroblasts throughout connective tissue, stimulating collagen production and suppressing matrix-degrading enzymes like MMP-9. This systemic fibroblast activation supports cartilage maintenance and collagen preservation even in avascular cartilage.
Can Cartalax reverse osteoarthritis or just prevent progression?
Russian clinical studies show efficacy in established osteoarthritis, osteochondrosis, and osteoporosis treatment. However, 'reverse' is overstated—Cartalax supports tissue repair and slows degeneration better than it rebuilds severely damaged cartilage. Results are best when cartilage damage is moderate, not advanced.
How long before joint pain improves on Cartalax?
Week 1-2 establishes baseline; minimal noticeable changes. Week 3-4 brings gradual improvement in joint comfort. Month 2 shows noticeable mobility improvements. Month 3 achieves maximum therapeutic effect. Results are cumulative with repeat cycles; 1-3 month cycles repeated annually produce best long-term joint health.
Is Cartalax safe for long-term use or does it carry cancer risk from cell proliferation?
Cartalax increases fibroblast proliferation while suppressing apoptosis. Theoretical concern exists regarding uncontrolled cell growth, but Russian clinical practice spanning decades shows no documented malignancy risk. Avoid use in active cancer; for healthy individuals, cyclic use (1-3 months on, breaks between) minimizes theoretical proliferation risk.
References
- Fibroblast Proliferation Study(2019)
Human skin fibroblasts; 72 hours at 20 nM. Increased Ki-67 expression with suppressed apoptosis in young and aged cells.
- Kidney Cell Culture Research(2020)
Renal epithelial cells; 7 days. Reduced pro-apoptotic p53 expression in aging kidney cells.
- Clinical Spine & Joint Study (Russia)(N/A)
Human subjects; 1-3 months with 0.1mg capsules daily. Efficacy in osteochondrosis, osteoarthritis, and osteoporosis treatment.
- Matrix Metalloproteinase Research(2020)
Fibroblast cultures; 5 days at 20 nM. Inhibited MMP-9 synthesis; maintained extracellular matrix integrity.
Related Peptides
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.
For education and research information only. Not individualized medical advice.